Motif Bio Share Discussion Threads

[banshee] 01/3/2019 19:05

Up sharply on the Nasdaq, currently +15% or so FWIW.

[lionheart69uk1] 01/3/2019 17:03

That says more about your inadequacies (Badger) rather than anything else. If you check the tradings over the past few days, you will see that the Buy/Sell split is roughly 50:50 and I myself know of people starting to buy at these prices.

[badger60] 01/3/2019 16:15

Nobody that I know is buying Motif in any way shape or form.....

[comedy] 01/3/2019 16:14

keep up the good work badger as your mates get their fill of a nice placing..then hey presto...all your posting will be 10 years out of date???

[badger60] 01/3/2019 16:11

#3500 not my words...taken from this article

[badger60] 01/3/2019 16:07

Regardless, the reason for the original FDA rejection seems to be somewhat serious, imo.Maybe Motif have solved it.....maybe they haven't....

[banshee] 01/3/2019 16:01

You seem a bit confused about the nature of the term "spinout", Arpida ceased to be part of Roche in 1998 and acquired Iclaprim from them in 2001. All this happened a long time before the first FDA submission and so Roche had nothing to to do with dropping Iclaprim after consulting the FDA post rejection as you are claiming.

The QT issue was addressed by altering the delivery system, there were no QT issues in the recent trials - that is why is was not mentioned in the CRL, while the liver data seems no worse than that for Paratek, who recently gained approval for their anitbiotic.

[badger60] 01/3/2019 15:53

The QT interval is inversely proportional to heart rate:The QT interval shortens at faster heart ratesThe QT interval lengthens at slower heart ratesAn abnormally prolonged QT is associated with an increased risk of ventricular arrhythmias, especially Torsades de Pointes.Congenital short QT syndromehas been found to be associated with an increased risk of paroxysmal atrial and ventricular fibrillation and sudden cardiac death.

[badger60] 01/3/2019 15:40

Arpida, a Roche spinout, had taken its Phase III data to regulators in 2009, but was handed its walking papers after an outside panel voted overwhelmingly against an approval, noting that evidence of QT prolongation and a disproportionate number of deaths in the iclaprim arm should preclude any further work on the antibiotic.The setback scuttled Arpida. But before the company was bought out by Evolva, icalprim was spun out to a company called Nuprim, which the wikipedia page for the antibiotic says was created by an executive at Arpida. Then Motif, looking to switch into late-stage development, picked it up before going public.

[comedy] 01/3/2019 15:27

lol is it friday time jackanory at the badger's home???

[banshee] 01/3/2019 15:25

Roche let it go it well before the first FDA submission that ended in rejection in fact, not post, letting it be be spun out into Arpida, at a time when big pharma generally was losing interest in antibiotics as being insufficiently profitable to develop.

[comedy] 01/3/2019 13:40

lol yep pwhite seems badger hasnt got a scoby how drugs are developed,,, how many compounds are tried and discarded???

and how many others try to determine when a patent is granted, how to manipulate the chemical structure around the patent compund so they can create a new drug that has a better profile.

mtfb is a massive opportunity:)

[pwhite73] 01/3/2019 11:01

comedy I agree the market is out of the sync at the moment but this will change after the capital raise. And please remind that blithering idiot that 10 years of laboratory work has taken place since the FDA rejected iclaprim by Roche.

[comedy] 01/3/2019 10:05

pwhite either bod get a big partner in and sell a % of the share??? or placing at reasonable price and cheaper warrants to sweeten the deal???

I think we all agree £1billion valuation only after fda approval and maybe once the sales start???

but current m/cap is out of synch...

and obvious manipulation taking place with the "AT" trades holding share price down

[badger60] 01/3/2019 08:34

You are the epitome of stupidity and boredom........or is it boredom and stupidity......

[pwhite73] 01/3/2019 08:26

Your $1bn valuation before commercial sales is wildly optimistic. What you also have to bear in mind is a change of ownership from institutions to fickle PIs. Furthermore Motif does not currently have anything like the cash to take the company to commercialisation therefore further capital will be required or a partnership. If Motif wants to keep 100% of its product it will need to raise further case and much more. I do believe there will be a share price rise once the meeting with the FDA is completed but this has to be sensibly tempered against how they intend to raise capital.

The share price is not stuck at 7p for nothing.

[comedy] 01/3/2019 08:20

ps why would co. issue £70mill in stock??? lol they need a tenth of that if??? think you are getting your decimal places in the wrong places...and even then pi's will make money.:)